evipedia.ai
← Back

HMR Lignans for Health & Longevity

Evidence Review created on 09/12/2026 using AI4L / Opus 5

Also known as: 7-Hydroxymatairesinol, 7-HMR, HMRlignan, Hydroxymatairesinol, HMR/lignan, Norway Spruce Lignan

Motivation

HMR lignans (7-hydroxymatairesinol) are plant compounds drawn from the knotwood of the Norway spruce, a part of the tree long discarded by the forestry industry. Taken orally, they are absorbed quickly, and bacteria in the large intestine convert the remainder into enterolactone, a weakly estrogen-like substance that circulates in the blood for about a day. Interest in the compound rests almost entirely on enterolactone: decades of population research have tracked how much of it people carry and how they fare over time.

Lignans reach the body mainly through whole grains, seeds and berries, and habitual intake in Western diets is low. Spruce knotwood was the first source concentrated enough to make a purified oral product practical, and such a product has been sold since the early 2000s, first for menopausal complaints and later for metabolic and prostate interest.

This review sets out what is established and what is not: how the compound behaves in the body, which effects have been measured in people rather than in animals or cell cultures, how benefit and harm evidence is distributed, who produced that evidence, and what a documented regimen looks like.

Benefits - Risks - Protocol - Conclusion

High-level sources that discuss HMR lignans, or the enterolactone pathway they feed, in enough depth to orient a reader before the evidence sections.

Only Life Extension among the priority platforms meets the depth bar. Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser and Lifespan.io mention lignans at most in passing, so remaining slots come from the primary literature.

Grokipedia

No Grokipedia article exists for HMR lignans. Grokipedia has no entry for 7-hydroxymatairesinol, HMRlignan or spruce lignan; only a general article on the lignan class as a whole.

Examine

No Examine article exists for HMR lignans. Examine.com has no supplement page for 7-hydroxymatairesinol, spruce lignan or the lignan class.

ConsumerLab

No ConsumerLab article exists for HMR lignans. ConsumerLab has never published a product review, answer or clinical update on 7-hydroxymatairesinol or spruce lignan supplements.

Systematic Reviews

No systematic review or meta-analysis covers 7-hydroxymatairesinol itself, so the papers below pool the lignan class and serum enterolactone — the metabolite HMR lignans raise — across the outcomes most often claimed for them.

Mechanism of Action

7-Hydroxymatairesinol (7-HMR) is a plant lignan, making up roughly 65–80% of the lignan content of Norway spruce (Picea abies) knotwood. Taken orally it is absorbed rapidly; over 96% of what circulates is conjugated, meaning sugar or sulfate groups are attached for excretion. Colonic bacteria then convert the remainder to enterolactone, the mammalian lignan carrying most of its presumed activity (Saarinen et al., 2000; Udani et al., 2013).

Enterolactone binds both estrogen receptor subtypes weakly, acting as a mild activator when the body’s own estrogen is low and a competitor when it is high. Independently of receptors, 7-HMR suppresses NF-κB (nuclear factor kappa B, a master switch for inflammatory genes) and ERK (extracellular signal-regulated kinase, a growth-signal relay) while switching on Nrf2/HO-1 (a protein pair that turns up the cell’s own antioxidant enzymes) (Yang et al., 2017).

Two accounts compete: one treats the compound as a phytoestrogen (plant-derived estrogen-mimic) acting through receptors, the other as a receptor-independent antioxidant, since the founding rodent work found no estrogenic or antiestrogenic activity in the rat uterine growth test (Saarinen et al., 2000).

Pharmacologically: absorption exceeds 50%, parent 7-HMR peaks near one hour and clears rapidly, no terminal half-life is published in humans, distribution is broad but shallow, without accumulation, enterolactone peaks near 24 hours, sustained by biliary reabsorption, and clears in urine; metabolism is two-stage — bacterial conversion in the colon, then UGT and SULT enzymes (which tag compounds for excretion) in gut wall and liver, not cytochrome P450 (the liver’s main drug-oxidising enzymes).

Historical Context & Evolution

Norway spruce knots were a nuisance to Finnish pulp mills before wood chemists at Åbo Akademi University showed in the late 1990s that they hold 6–16% lignans by weight, most of it 7-HMR. The original intended use was not a supplement at all: Hormos Nutraceutical of Turku developed the purified compound as HM-3000, a candidate chemopreventive and antioxidant drug, and ran it through antioxidant assays, two rodent tumour models, rat and dog toxicology and first-in-human dosing (Kangas et al., 2002). Those authors were employed by the developer, the first instance of a pattern that runs through this literature.

The move toward health optimisation came from Herman Adlercreutz’s observation that populations with low breast and prostate cancer rates excrete far more enterolactone. Spruce lignan was attractive because rodent work showed it converts to enterolactone more efficiently than flaxseed lignans do, offering a direct way to raise the marker (Saarinen et al., 2000).

Drug development stopped; the molecule was licensed to Linnea SA and sold as HMRlignan. What changed since is the cohort evidence on both sides: measured-enterolactone studies continued to show mortality associations (Rienks et al., 2017), while pooled individual-participant data found no prostate cancer link (Perez-Cornago et al., 2018) and breast cancer prognosis split by menopausal status (Liu et al., 2021). The enterolactone hypothesis has neither been confirmed nor overturned — it has been narrowed, and the tumour findings that motivated it remain unreplicated in people.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only human trial of HMR lignans is a small, single-blind dose-comparison without a placebo arm, so no clinical endpoint and no outcome-validated clinical surrogate have been demonstrated in more than one controlled trial.

Medium 🟩 🟩

No benefit reaches Medium: no human clinical endpoint, and no clinical surrogate validated against outcomes in people, has been measured for HMR lignans in a single controlled trial or in consistent observational data on the compound itself.

Low 🟩

Sustained Elevation of Circulating Enterolactone

Oral 7-HMR raises the metabolite that carries its presumed activity, the exposure measure population studies actually track. Eight weeks of dosing in postmenopausal women raised both parent compound and metabolite, and an earlier volunteer series showed partial conversion (Kangas et al., 2002). The trial had no placebo arm.

Magnitude: Plasma 7-HMR rose 191% at 36 mg/day and 1238% at 72 mg/day over 8 weeks; plasma enterolactone rose 157% and 137% respectively, peaking at 4.8 ng/mL about 24 hours after a dose (Udani et al., 2013).

Reduction in Menopausal Hot Flashes

The single human trial recorded a halving of weekly hot flashes at the higher dose over eight weeks, with a smaller significant fall at the lower dose. It was single-blinded, had no placebo group and only 22 participants. Pooled plant-estrogen trials (Chen et al., 2015) make the direction plausible.

Magnitude: Mean hot flashes fell from 28.0 to 14.3 per week, a 50% reduction, at 72 mg/day over 8 weeks, and by 44% at 36 mg/day (Udani et al., 2013).

Lower Cardiovascular and All-Cause Mortality

Higher circulating enterolactone tracks lower mortality in cohorts that measured the metabolite rather than estimating diet. This is indirect: the enterolactone came from food, and no trial has tested whether raising it with 7-HMR changes mortality. Reverse causation is plausible, since enterolactone also marks a fibre-rich diet.

Magnitude: Higher versus lower enterolactone concentrations were associated with roughly 30% lower all-cause and 45% lower cardiovascular mortality (Rienks et al., 2017).

Lower Incidence of Type 2 Diabetes

Twelve prospective cohorts found higher dietary lignan intake tracking lower diabetes incidence with a graded dose-response. The exposure is class-level dietary lignan, not 7-HMR, and no trial has measured glucose outcomes on the purified compound in people; the supporting mechanistic work is in mice.

Magnitude: Highest versus lowest lignan intake gave a relative risk (the rate of an event in one group divided by the rate in another) of 0.82 (95% confidence interval, the range the true value most likely falls in: 0.68–0.99), with a relative risk of 0.96 per 500 µg/day increment (Xia et al., 2023).

Lower Postmenopausal Breast Cancer Risk ⚠️ Conflicted

Pooled observational data link higher lignan intake to fewer breast cancer diagnoses after menopause, the observation that launched interest in the class. Measured blood enterolactone, the exposure 7-HMR actually raises, showed no such association. Net reading: the signal attaches to dietary intake, not to the metabolite a supplement delivers.

Magnitude: Highest versus lowest lignan intake gave a pooled risk estimate of 0.86 (95% confidence interval 0.78–0.94) in postmenopausal women, while blood enterolactone concentration showed no association (Buck et al., 2010).

Postmenopausal Breast Cancer Survival ⚠️ Conflicted

Pooled cohorts of women diagnosed with breast cancer found better survival at higher lignan intake and enterolactone after menopause, and worse survival before it; recurrence showed no association. Net reading: the survival signal is real but confined to the postmenopausal subgroup, the opposite signal appearing below as a risk.

Magnitude: Postmenopausal pooled hazard ratio (the relative rate at which an event occurs over time) 0.73 (95% confidence interval 0.58–0.91) for all-cause and 0.72 (0.60–0.87) for breast-cancer-specific mortality (Liu et al., 2021).

Prostate Cancer Risk ⚠️ Conflicted

Spruce lignan shrank human prostate tumour grafts in mice, and the marketing case rests on that. Human blood-measurement studies disagree: pooled individual participant data across seven cohorts found no association, and a separate meta-analysis returned a null for enterolactone. Net reading: human evidence does not support a prostate benefit.

Magnitude: Enterolactone versus prostate cancer odds ratio (the relative odds of an outcome between two groups) 0.94 (95% confidence interval 0.73–1.20), a null result (Zhang et al., 2017).

Speculative 🟨

Tumour Suppression in Rodent Cancer Models

Basis is animal work only. Oral 7-HMR slowed chemically induced mammary tumour growth in rats and reduced intestinal polyp formation in a genetically predisposed mouse strain. Neither finding has a human counterpart.

Endothelial Anti-Inflammatory Activity

Basis is cell culture only. In human aortic endothelial cells 7-HMR cut adhesion-molecule expression and monocyte sticking; in human monocytes it suppressed inflammatory signalling. No human inflammatory endpoint has been measured.

Improved Body Composition and Glucose Handling

Basis is animal and cell work only. Mice on a high-fat diet given purified 7-HMR gained less weight and fat, showed less liver fat, and had markedly lower insulin resistance; fat-cell cultures showed blocked differentiation.

Lowered Blood Lipids

Basis is rodent dosing only. Thirteen weeks of dietary 7-HMR depressed plasma triglycerides across dose groups and total cholesterol at the top dose (Lina et al., 2005); the human trial measured no lipid change.

Protection of Dopamine-Releasing Nerve Endings

Basis is a single rodent model. Four weeks of oral 7-HMR slowed the loss of dopamine-releasing nerve endings and improved movement in chemically injured rats, though the nerve cell bodies themselves were unprotected.

Direct Antioxidant Capacity

Basis is in-vitro assays only. 7-HMR outperformed vitamin E analogues and synthetic food antioxidants in lipid peroxidation and radical scavenging tests. Antioxidant assay results are unvalidated as predictors of any human outcome.

Support of Iron Absorption in Inflamed Bowel

Basis is a hypothesis tested in gut cell cultures. Because 7-HMR lowers inflammatory signalling that drives hepcidin — the hormone locking iron inside cells — it was proposed to ease anaemia in celiac disease. Untested in people.

Benefit-Modifying Factors

  • Gut microbiome composition: Conversion of 7-HMR to enterolactone is done entirely by colonic bacteria. Low microbial diversity, low fermentable fibre intake or a recent antibiotic course reduces the yield, and some people convert poorly no matter the dose.

  • Baseline enterolactone: Those starting with low circulating enterolactone — typical of low-fibre Western eating — have the most headroom. Someone already eating flaxseed, rye and berries daily gains proportionally less from supplementation.

  • Endogenous estrogen level: Plant estrogens act as weak activators when the body’s own estrogen is low and as competitors when it is high, so the same dose behaves differently before, during and after the menopausal transition.

  • Sex-based differences: Every human outcome measured so far comes from postmenopausal women. Male data exist only as observational enterolactone-and-prostate research, which is null, so the benefit profile in men is essentially uncharacterised.

  • Pre-existing health conditions: Celiac disease, inflammatory bowel disease and prior bowel resection alter both bacterial conversion and absorption. Hormone-sensitive cancers change the sign of the expected effect rather than its size.

  • Genetic polymorphisms: Variants in UGT and SULT conjugating enzymes (which attach handles to compounds for excretion) alter how long free lignan circulates; ESR1 and ESR2 variants (the two estrogen receptor genes) alter downstream response.

  • Age-related considerations: Microbial diversity declines with age, so adults in their seventies and eighties may convert less efficiently than younger adults at the same dose. No trial has compared conversion across age bands.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome has been documented in more than one controlled human trial, because the entire human safety record consists of short-duration dosing studies that reported no treatment-related adverse events.

Medium 🟥 🟥

No risk reaches Medium: no single controlled human trial and no consistent observational dataset reports an adverse clinical outcome for 7-hydroxymatairesinol itself; the human outcome data that exist measure dietary lignan intake or enterolactone as a class exposure.

Low 🟥

Worse Survival in Premenopausal Breast Cancer ⚠️ Conflicted

In pooled cohorts of women with breast cancer, higher lignan intake and enterolactone tracked better survival after menopause but worse survival before it. The exposure was dietary and the premenopausal estimate rests on fewer cases. Net reading: weak and indirect, but the most relevant caution for premenopausal hormone-receptor-positive disease.

Magnitude: Premenopausal pooled hazard ratio 1.57 (95% confidence interval 1.11–2.23) for all-cause mortality, highest versus lowest exposure (Liu et al., 2021).

Speculative 🟨

Proliferation of Estrogen-Sensitive Breast Cells

Basis is cell culture only. In estrogen-responsive human breast cancer cells, both 7-HMR and enterolactone pushed more cells into the growth phase and raised the survival-to-death protein ratio, blocked by an estrogen receptor antagonist.

Reduced Ovarian Weight and Lengthened Estrous Cycle

Basis is a single rodent toxicology study. Female rats fed 7-HMR for thirteen weeks showed lower ovary weights at every dose and a longer cycle at the top dose; this endpoint set the no-observed-adverse-effect level.

Platelet and White Cell Count Shifts

Basis is the same rodent study, top dose only. Platelet counts rose in females and white cell counts in males at an intake far above any human dose. No human haematology change has been reported.

Gastrointestinal Discomfort

Basis is isolated consumer reports rather than trial data. Mild bloating or loose stools are occasionally described with lignan supplements; the one human trial recorded no significant safety issues at up to 72 mg daily.

Unknown Effects in Pregnancy and Lactation

Basis is animal work and absence of data. Rat fetuses showed no structural abnormalities at any dose, but high-dose dams ate less and lost weight, and no human pregnancy exposure has ever been studied.

Risk-Modifying Factors

  • Hormone-receptor status: Estrogen-receptor-positive or progesterone-receptor-positive breast or endometrial disease converts a weak plant estrogen from neutral to potentially counterproductive. Receptor status, not cancer history alone, is the discriminating variable.

  • Menopausal status: The one adverse human signal is confined to premenopausal women, matching the pharmacology: weak plant estrogens compete with abundant endogenous estrogen before menopause and substitute for absent estrogen after it.

  • Baseline biomarker levels: Low baseline enterolactone means a larger proportional rise from the same dose. Elevated baseline estradiol, or a rising prostate-specific antigen trend, changes how any subsequent movement should be interpreted.

  • Sex-based differences: Adverse-event data exist only in women. In men the compound’s relevance runs through prostate tissue, where human studies are null rather than reassuring, so male risk is unquantified rather than low.

  • Pre-existing health conditions: Bleeding disorders and planned surgery matter because of the rodent platelet finding. Celiac disease and inflammatory bowel disease alter conversion, changing exposure unpredictably in either direction.

  • Genetic polymorphisms: Reduced-function UGT and SULT variants slow conjugation and prolong free lignan exposure; CYP19A1 variants (the aromatase gene, which makes estrogen from androgens) shift the hormonal background the compound acts against.

  • Age-related considerations: Adults past seventy take more medicines at once and clear conjugates more slowly through the kidneys, and are the group least represented in the dosing studies, none of which enrolled beyond ordinary postmenopausal ages.

Key Interactions & Contraindications

  • Tamoxifen and other selective estrogen receptor modulators (raloxifene): Caution. Competition at the same receptor could blunt or alter the drug’s effect. No human interaction study exists; protocols avoid concurrent use rather than monitor it.

  • Aromatase inhibitors (anastrozole, letrozole, exemestane): Caution. These drugs work by driving estrogen signalling to near zero; adding a weak receptor activator works against that goal. Protocols withhold the supplement for the duration of therapy rather than dose-adjust.

  • Menopausal hormone therapy (estradiol, conjugated estrogens): Monitor. Effects on hot flashes overlap, so the supplement adds little while complicating attribution of any symptom change. Separating the two by at least eight weeks is what comparison requires.

  • Broad-spectrum antibiotics (amoxicillin, ciprofloxacin, clindamycin): Monitor. They suppress the colonic bacteria that make enterolactone, so the supplement can stop working entirely. Assessment is meaningful again only two to four weeks after the course ends.

  • Warfarin and antiplatelet agents (aspirin, clopidogrel): Caution. Rodent dosing shifted platelet counts and several dietary phenolics dampen platelet responsiveness. Bruising is the sign to track, and protocols stop the supplement one to two weeks before planned surgery.

  • Over-the-counter nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen): Caution. The concern is additive effect on platelet function rather than a metabolic interaction. Occasional use is unremarkable; daily use alongside the supplement warrants watching for bruising.

  • Over-the-counter bulk laxatives and binders (psyllium, activated charcoal): Monitor. Both can adsorb the lignan or speed transit past the colonic bacteria that convert it. A dosing gap of at least two hours is the usual separation.

  • Other lignan supplements (flaxseed lignan, sesame lignan): Monitor; additive exposure. All converge on the same enterolactone pool, so combining them multiplies exposure without adding a distinct mechanism. The relevant quantity is total lignan intake, not the number of capsules.

  • Soy isoflavones, red clover and hops extracts: Caution; additive. Each acts at estrogen receptors, so combination products — commonly sold for menopause — deliver a larger total plant-estrogen load than the label for any single ingredient suggests.

  • Probiotics and fermentable fibre: Monitor; potentiating. Supporting the converting bacteria raises enterolactone yield from the same dose, which is desirable for effect but means a dose set before a microbiome change may become a different exposure after it.

Populations who should avoid HMR Lignans:

  • Premenopausal women with a current or prior diagnosis of estrogen-receptor-positive or progesterone-receptor-positive breast cancer (any stage), given the opposite-direction survival signal in this subgroup
  • Anyone on active endocrine therapy for breast or endometrial cancer (tamoxifen, any aromatase inhibitor), for the duration of treatment
  • Pregnancy and lactation, at any dose — no human exposure data exist
  • Children and adolescents under 18, for the same reason
  • People with an inherited bleeding disorder, or within 14 days of planned surgery
  • People with unexplained vaginal bleeding or an undiagnosed endometrial thickening on imaging, until the cause is established

Risk Mitigation Strategies

  • Receptor status before starting: The estrogen- and progesterone-receptor status of any prior breast or endometrial cancer comes first, because that single fact separates the neutral case from the premenopausal survival signal.

  • Four-week run-in at 36 mg daily: The lower of the two studied doses produced the enterolactone rise and most of the hot-flash effect. Beginning there and escalating to 72 mg surfaces gastrointestinal intolerance before full exposure.

  • Ceiling of 144 mg daily: The longest human dosing record runs to 144 mg for twelve weeks. Staying inside that ceiling keeps exposure within the range where the absence of adverse events was actually observed.

  • Conversion check at eight weeks: Measuring serum enterolactone after two months shows whether the colonic bacteria are producing it. A flat result means the exposure that everything else rests on is not occurring.

  • Pause around antibiotic courses: Restarting assessment two to four weeks after a broad-spectrum course avoids mistaking suppressed bacterial conversion for lack of response, and avoids escalating the dose for the wrong reason.

  • 14-day stop before surgery or dental extraction: This covers the rodent platelet-count finding and the additive antiplatelet concern with aspirin or nonsteroidal anti-inflammatory drugs, neither of which has been quantified in people.

  • Annual prostate-specific antigen in men over 45: Human data give no prostate benefit, so the marker is watched to detect change rather than to demonstrate effect, using the same assay and laboratory each time.

Therapeutic Protocol

  • Standard dose: 36–72 mg of 7-HMR daily as a single oral dose, the range used in the eight-week human study. European supplement labelling commonly specifies 72–144 mg daily as one or two capsules.

  • Purified spruce lignan approach: One capsule of standardised 7-HMR daily, taken indefinitely and judged on symptom change plus serum enterolactone. This is the regimen the ingredient developer built and the only one with human dosing data behind it.

  • Whole-food lignan loading approach: 20–40 g of ground flaxseed daily supplies secoisolariciresinol diglucoside, a different lignan feeding the same enterolactone pool, with fibre and alpha-linolenic acid alongside but slower, less efficient conversion.

  • Combination phytoestrogen approach: Integrative practitioners and Life Extension — which sells such formulas and therefore has a commercial interest in the framing — pair spruce lignan with hops-derived 8-prenylnaringenin for hot flashes rather than using either alone.

  • Who popularised each: Hormos Nutraceutical and then Linnea SA developed the purified ingredient; Jay Udani’s Medicus Research ran the human dosing trial; flaxseed loading traces to Herman Adlercreutz’s enterolactone work in Helsinki.

  • Best time of day: Morning with food. Because enterolactone peaks about 24 hours after a dose and parent compound clears within hours, clock time matters far less than taking it at the same time each day.

  • Half-life: Parent 7-HMR peaks near one hour and clears rapidly; no formal terminal half-life is published in humans. Enterolactone peaks near 24 hours, which is what makes once-daily dosing coherent.

  • Single versus split dosing: Every human study used a single daily dose, and the 24-hour metabolite peak means splitting adds nothing. Split dosing appears only where a single dose causes gastrointestinal upset.

  • Genetic polymorphisms: Reduced-function UGT and SULT variants prolong free lignan exposure and argue for the lower dose; ESR1 variants may alter response magnitude. No pharmacogenetic dosing rule has been validated for this compound.

  • Sex-based differences: All dosing data come from postmenopausal women. Men use the same range by extrapolation only, since no male dose-ranging study has been published and the male outcome data are null.

  • Age-related considerations: No dose reduction is established for older adults, but declining microbial diversity past seventy makes a confirmed enterolactone rise more informative than dose escalation when response is absent.

  • Baseline biomarker levels: A low starting enterolactone predicts the largest proportional rise. Where baseline is already high from a seed- and rye-heavy diet, the marginal exposure gain from supplementation is small.

  • Pre-existing health conditions: Celiac disease, inflammatory bowel disease and prior bowel resection change both absorption and bacterial conversion, so measured enterolactone rather than dose should guide these cases.

Discontinuation & Cycling

  • Intended duration: Documented human use runs eight to twelve weeks. Longer use is entirely extrapolation, so the compound sits closer to a defined trial period judged on measured response than to a lifelong commitment.

  • Withdrawal effects: None reported. Parent compound clears within hours and enterolactone within a few days, so stopping simply returns circulating lignan to whatever the diet supplies.

  • Tapering: Not applicable. No receptor upregulation, dependence or rebound has been described for plant lignans, and both human studies ended dosing abruptly without incident.

  • Cycling for efficacy: No evidence supports cycling. No tolerance has been documented, and because the effect depends on continuous bacterial conversion, interrupting supply lowers enterolactone rather than resetting any response.

  • Stopping for a hard reason: Discontinuation is warranted on a new hormone-receptor-positive diagnosis, before surgery, or when an eight-week enterolactone measurement shows no rise despite adherence at the upper dose.

Sourcing and Quality

  • Branded versus generic material: Nearly all human and toxicology data were generated on HMRlignan from Linnea SA, a potassium acetate complex of 7-HMR. Generic “spruce lignan” powders have no published characterisation.

  • Standardisation to 7-HMR: The label should state milligrams of 7-hydroxymatairesinol, not milligrams of extract. Spruce knot extract is only 6–16% lignan by weight, so extract weight overstates delivered dose several-fold.

  • Distinguishing lignan types: Products labelled simply “lignans” are usually flaxseed secoisolariciresinol diglucoside, a different molecule with different conversion efficiency. The source species belongs on the label, not just the word lignan.

  • Third-party testing: NSF International, United States Pharmacopeia and Informed Choice certifications cover identity and potency. Lignan content cannot be judged by appearance, and botanical extracts are a category with recurrent identity substitution.

  • Formulation and stability: The potassium acetate complex exists to improve handling of an otherwise poorly soluble solid. Capsules stored cool and dry are appropriate; lignans degrade under prolonged heat, which rules out baking them into foods.

  • Reputable suppliers: Finished products built on the Linnea material are sold by Swanson and, in combination menopause formulas, by Life Extension — a company that both publishes on lignans and profits from selling them.

Practical Considerations

  • Time to effect: Serum enterolactone rises within days of the first dose. The only measured symptom endpoint, hot-flash frequency, was assessed at eight weeks, so that is the realistic window before judging response.

  • Pitfall — confusing the lignans: Buying flaxseed lignan expecting spruce lignan data, or the reverse, is the most common error. They share a metabolite but differ in molecule, conversion efficiency and the evidence attached to them.

  • Pitfall — ignoring the microbiome: Dose escalation cannot compensate for absent converting bacteria. Someone recently on antibiotics or eating very little fermentable fibre may see no enterolactone rise at any dose.

  • Pitfall — reading rodent tumour data as human evidence: The prostate and mammary tumour results that drive marketing come from human tumours grafted into mice and from chemically induced rodent cancers. Human blood-measurement studies are null, and the gap is not a matter of dose.

  • Regulatory status: In the United States 7-HMR is sold as a dietary supplement ingredient with no approved medical indication. In the European Union it falls under the novel-food framework, with a dossier for the potassium acetate complex filed in 2019.

  • Cost and payer incentives: Daily cost is modest, roughly that of a common vitamin, but no insurer reimburses it, whereas generic menopausal hormone therapy is covered. That asymmetry favours the pharmaceutical comparator in guideline formation and trial funding.

Interaction with Foundational Habits

  • Sleep: Indirect and potentially favourable. The compound has no sedative or stimulant action and does not act on sleep architecture. Any benefit runs through fewer night-time hot flashes, which improves sleep continuity. No sleep endpoint has been measured in any human study, so this remains inference from the symptom result.

  • Nutrition: Direct and decisive. Conversion to enterolactone happens only in the colon, so fermentable fibre from rye, oats, legumes and vegetables sustains the bacteria doing the work. Dietary lignans from flaxseed, sesame and berries feed the same pool and count toward total exposure. Dosing is with food; heat-processed products lose lignan content.

  • Exercise: No direct interaction known. Nothing suggests blunting of hypertrophy or endurance adaptation, since the compound does not act on the antioxidant-sensitive signalling implicated in that debate. Timing relative to training is irrelevant given the 24-hour metabolite peak. Endurance training independently raises gut microbial diversity, which may modestly improve conversion.

  • Stress management: Indirect and unmeasured. No human study has assessed cortisol, heart-rate variability or any stress endpoint with 7-HMR. The only plausible link is that fewer hot flashes lower day-to-day physiological strain. Standard practices remain the operative lever here, with the compound contributing nothing measurable in either direction.

Monitoring Protocol & Defining Success

Baseline testing exists to establish two things: whether the hormonal setting makes this compound sensible, and what the starting exposure actually is. Before a first dose, a reasonable panel covers serum enterolactone, high-sensitivity C-reactive protein (hs-CRP, a fine-grained marker of low-level inflammation), a fasting lipid panel including low-density lipoprotein cholesterol (LDL-C, the cholesterol-carrying particle that drives artery plaque), haemoglobin A1c (HbA1c, average blood sugar over three months), alanine aminotransferase (ALT, a liver enzyme), and — in men over 45 — prostate-specific antigen (PSA, a protein made by the prostate that rises with prostate disease). For women still cycling, estradiol and follicle-stimulating hormone place the individual within the menopausal transition. Ongoing monitoring is sparse by design: repeat enterolactone and hs-CRP at 8 weeks, repeat the full panel at 6 months, then every 6–12 months while use continues.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum enterolactone No established target; track a rise from the individual’s own baseline, typically 2–3-fold by week 8 Confirms colonic bacteria are converting the dose; a flat result means no exposure Specialty and research laboratories only; not on routine panels. Fasting not required. Paired with a diet record, since food lignans move it too
hs-CRP Below 1.0 mg/L Tracks the low-grade inflammation the compound’s cell-culture mechanism targets Conventional reference is below 3.0 mg/L. Testing is deferred for 2 weeks after infection, injury or hard training, which transiently inflate it
LDL-C 70–100 mg/dL (1.8–2.6 mmol/L) Rodent dosing lowered cholesterol; establishes whether any lipid movement occurs in people Conventional reference is below 130 mg/dL. Requires a 10–12 hour fast. Best paired with apolipoprotein B, which counts particles rather than cargo
Triglycerides Below 90 mg/dL (1.0 mmol/L) The clearest lipid change seen in rodent dosing, and the most diet-sensitive lipid Conventional reference is below 150 mg/dL. Requires a 10–12 hour fast and 3 alcohol-free days; a single high-fat meal distorts the result
HbA1c 5.0–5.4% Puts the observational diabetes-incidence signal to an individual test Conventional reference is below 5.7%. No fasting needed. Falsely low with shortened red-cell lifespan, as in haemolysis or recent blood loss
ALT 10–26 U/L (women), 10–30 U/L (men) Routine safety check, since long-term human exposure data do not exist Conventional upper limits run to 40–55 U/L. Fasting preferred. Strenuous exercise in the prior 48 hours raises it independently of the liver
PSA (men over 45) Below 1.0 ng/mL under 60; below 1.5 ng/mL thereafter Human data show no prostate benefit, so the marker detects change rather than confirms effect Conventional threshold is 4.0 ng/mL. Requires 48 hours without ejaculation, cycling or prostate examination; the same laboratory each time
Estradiol (women in transition) No established target for this purpose; interpret against menstrual status rather than a cut-off Places the individual on the estrogen gradient that determines whether a plant estrogen activates or competes Drawn on day 3 of the cycle if still menstruating. Paired with follicle-stimulating hormone, which rises as ovarian output falls

Qualitative markers worth tracking alongside the laboratory work:

  • Hot-flash frequency and severity, recorded as a simple daily count rather than recalled at the visit
  • Sleep continuity, specifically night-time waking attributable to heat or sweating
  • Daytime energy and exercise tolerance at a fixed workload
  • Mood stability and irritability across the menstrual or weekly cycle
  • Digestive comfort, since bloating is the most commonly described complaint

Emerging Research

  • No registered trial of the compound itself: A ClinicalTrials.gov search returns no interventional study of 7-hydroxymatairesinol, spruce lignan or HMRlignan. Everything below tests neighbouring lignans, so it informs the class rather than the ingredient, and could move the case either way.

  • Microbiome as the gatekeeper of cardiovascular benefit: The CardioFlax study (NCT04179136, 45 healthy volunteers, completed) gave flaxseed lignan capsules against placebo with flow-mediated dilation — an ultrasound measure of artery flexibility — as the primary endpoint, testing whether converter status decides who responds.

  • Lignan supplementation and gene expression in perimenopausal women: A placebo-controlled study (NCT07310485, 50 participants, enrolling by invitation) measures gene-expression change and premenstrual symptoms in healthy women aged 40–55 who are still cycling, close to the group in which the observational survival signal runs the wrong way.

  • Replication of the hot-flash result: The single positive symptom finding (Udani et al., 2013) has never been repeated against placebo. Set against the pooled plant-estrogen trials (Chen et al., 2015), a properly blinded replication is the study that would most change the picture.

  • Findings that could weaken the case: Pooled individual-participant data found no prostate association (Perez-Cornago et al., 2018), and breast cancer survival splits by menopausal status (Liu et al., 2021). Larger cohorts with measured enterolactone could harden either result.

  • Neurodegeneration as a new direction: Oral 7-HMR slowed the loss of dopamine-releasing nerve endings in chemically injured rats (Giuliano et al., 2020). Work funded in part by the ingredient’s manufacturer; independent replication in a second animal model would need to precede any human trial.

Conclusion

HMR lignans are a purified plant compound from Norway spruce knotwood whose entire case rests on one step: gut bacteria turn it into enterolactone, a weak estrogen-like substance that people carry in widely differing amounts. That conversion is the best-established fact about it, shown directly in people. Everything downstream is weaker. A single small study without a placebo group reported fewer hot flashes at the higher dose. The links to living longer, to fewer heart problems, to less diabetes and to fewer breast cancers after menopause come from watching what people eat and what they carry in their blood, not from giving anyone this product. The tumour findings that launched the compound come from mice and have not been reproduced in people, and pooled human data on the prostate found nothing.

On the other side, the same population data point the opposite way for women who have breast cancer before menopause, which is the one caution worth weighting heavily. Over the short term, no safety problems have been reported at the doses sold.

The evidence base is thin and unusually self-interested: the developer and licence-holder authored or funded much of the published work, and the most visible consumer article comes from a company selling lignan formulas. No independent, placebo-controlled work has been published.

Top - Benefits - Risks - Protocol